Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2019

Feb 11, 2020

SELL
$1.33 - $5.93 $55,195 - $246,095
-41,500 Closed
0 $0
Q3 2019

Nov 15, 2019

SELL
$5.12 - $7.21 $180,608 - $254,332
-35,275 Reduced 45.95%
41,500 $212,000
Q2 2019

Aug 14, 2019

BUY
$6.05 - $13.66 $215,228 - $485,954
35,575 Added 86.35%
76,775 $550,000
Q1 2019

May 14, 2019

BUY
$8.16 - $13.42 $336,192 - $552,904
41,200 New
41,200 $547,000
Q4 2018

Feb 13, 2019

SELL
$6.54 - $11.74 $236,584 - $424,694
-36,175 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$10.88 - $14.52 $393,584 - $525,261
36,175 New
36,175 $401,000

Others Institutions Holding CBAY

About CymaBay Therapeutics, Inc.


  • Ticker CBAY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 84,677,904
  • Description
  • CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...
More about CBAY
Track This Portfolio

Track Doheny Asset Management /Ca Portfolio

Follow Doheny Asset Management /Ca and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Doheny Asset Management /Ca, based on Form 13F filings with the SEC.

News

Stay updated on Doheny Asset Management /Ca with notifications on news.